Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

94
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

127
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
127
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

67
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
67
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

77
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

116
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
116
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

104
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
104

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGF12 Alleviates Cardiac Hypertrophy by Inhibiting Phosphorylation of CaM/CaMKII/CREB1 Axis.

Circulation. Genomic and precision medicine·2026
Same author

CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy.

Circulation·2026
Same author

RICNET: Retinex-Inspired Illumination Curve Estimation for Low-Light Enhancement in Industrial Welding Scenes.

Sensors (Basel, Switzerland)·2025
Same author

A Welding Defect Detection Model Based on Hybrid-Enhanced Multi-Granularity Spatiotemporal Representation Learning.

Sensors (Basel, Switzerland)·2025
Same author

Predictors of sudden cardiac death in postmyectomy hypertrophic cardiomyopathy with obstruction.

Heart rhythm·2025
Same author

Predictors of N-Terminal Pro-Brain Natriuretic Peptide Nonresponse and Its Impact on Outcomes in Patients After Septal Myectomy.

The Annals of thoracic surgery·2025

Related Experiment Video

Updated: Oct 19, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Hypertrophic cardiomyopathy in children.

Shuiyun Wang1, Changsheng Zhu1

  • 1Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, 571193Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Asian Cardiovascular & Thoracic Annals
|September 27, 2021
PubMed
Summary

Hypertrophic cardiomyopathy (HCM) in young people is a leading cause of sudden cardiac death (SCD). Surgical treatment and implantable cardioverter-defibrillators (ICDs) offer effective strategies for managing pediatric HCM and preventing SCD.

Keywords:
Hypertrophic cardiomyopathychildrensudden cardiac deathsurgical septal myectomy

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

Related Experiment Videos

Last Updated: Oct 19, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Sudden Cardiac Death Research

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most frequent cause of sudden cardiac death (SCD) in young individuals.
  • The causes and prognosis of pediatric HCM vary significantly based on presentation age and etiology.
  • Obstructive HCM in children presents complex challenges, yet surgical interventions can yield favorable outcomes.

Purpose of the Study:

  • To review the diverse etiologies and prognostic factors influencing pediatric hypertrophic cardiomyopathy.
  • To evaluate the efficacy of surgical treatment for obstructive HCM in carefully selected pediatric patients.
  • To discuss the role of implantable cardioverter-defibrillators (ICDs) in preventing SCD in pediatric HCM patients.

Main Methods:

  • Literature review of pediatric hypertrophic cardiomyopathy cases.
  • Analysis of outcomes for surgical interventions in obstructive HCM.
  • Assessment of current strategies for sudden cardiac death prevention using ICDs.

Main Results:

  • Surgical treatment in experienced centers provides favorable outcomes for selected pediatric obstructive HCM patients.
  • Implantable cardioverter-defibrillators (ICDs) are the most effective method for preventing sudden cardiac death.
  • A novel pediatric SCD risk prediction model shows promise for identifying patients who would benefit most from ICD implantation.

Conclusions:

  • Pediatric hypertrophic cardiomyopathy requires individualized management strategies based on etiology and presentation.
  • Surgical intervention and ICDs are crucial for improving outcomes and preventing sudden cardiac death in young patients with HCM.
  • Further refinement of pediatric SCD risk prediction models is needed to optimize ICD implantation decisions.